By Laura Ungar

A UK patient with a severely weakened immune system had COVID-19 for almost a year and a half, scientists reported, underscoring the importance of protecting vulnerable people from the coronavirus.

There’s no way to know for sure whether it was the longest-lasting COVID-19 infection because not everyone gets tested, especially on a regular basis like this case.

But at 505 days, “it certainly seems to be the longest reported infection," said Dr. Luke Blagdon Snell, an infectious disease expert at the Guy’s & St. Thomas' NHS Foundation Trust.

Snell's team plans to present several “persistent” COVID-19 cases at an infectious diseases meeting in Portugal this weekend.

Their study investigated which mutations arise — and whether variants evolve — in people with super long infections. It involved nine patients who tested positive for the virus for at least eight weeks. All had weakened immune systems from organ transplants, HIV, cancer or treatment for other illnesses. None were identified for privacy reasons.

Repeated tests showed their infections lingered for an average of 73 days. Two had the virus for more than a year. Previously, researchers said, the longest-known case that was confirmed with a PCR test lasted 335 days.

Persistent COVID-19 is rare and different from long COVID.

“In long COVID, it’s generally assumed the virus has been cleared from your body but the symptoms persist,” Snell said. “With persistent infection, it represents ongoing, active replication of the virus.”

Each time researchers tested patients, they analyzed the genetic code of the virus to make sure it was the same strain and that people didn't get COVID-19 more than once. Still, genetic sequencing showed that the virus changed over time, mutating as it adapted.

The mutations were similar to the ones that later showed up in widespread variants, Snell said, although none of the patients spawned new mutants that became variants of concern. There's also no evidence they spread the virus to others.

The person with the longest known infection tested positive in early 2020, was treated with the antiviral drug remdesiver and died sometime in 2021. Researchers declined to name the cause of death and said the person had several other illnesses.

Five patients survived. Two cleared the infection without treatment, two cleared it after treatment and one still has COVID-19. At the last follow-up earlier this year, that patient’s infection had lasted 412 days.

Researchers hope more treatments will be developed to help people with persistent infections beat the virus.

“We do need to be mindful that there are some people who are more susceptible to these problems like persistent infection and severe disease,” Snell said.

Although persistent infections are rare, experts said there are many people with compromised immune systems who remain at risk of severe COVID-19 and who are trying to stay safe after governments lifted restrictions and masks started coming off. And it's not always easy to know who they are, said Dr. Wesley Long, a pathologist at Houston Methodist in Texas, who was not part of the research.

“Masking in crowds is a considerate thing to do and a way we can protect others,” he said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Stoke Space Technologies Raises $65 Million to Develop Reusable Rockets
Reusable rocket developer Stoke Space Technologies raised $65 million in a Series A round led by Breakthrough Energy Ventures, a firm founded by Bill Gates. Stoke says its reusable rockets provide the satellite industry with low-cost, on-demand access to and from orbit. As companies like SpacX and Blue Origin are also making commitments to rocket reusability, Stoke says it is taking a different approach with a system designed to be 100% reusable, comprised of rockets designed to fly daily, like an airplane. Stoke co-founder and CEO Andy Lapsa joins Cheddar News' Closing Bell to discuss.
NASA's Artemis Program to Return Mankind to the Moon, Pave Way for Exploration of Mars
Humans are set to return to a place we have not been in nearly 50 years: the moon. NASA's Artemis program is expected to have astronauts back on the lunar surface by 2025. NASA says it will use what it learns on the moon to take the next giant leap - sending the first astronauts to Mars. The Artemis program also includes contributions from private companies like SpaceX, as well as academic research institutions like Georgia Tech. Georgia Tech professor of practice and former NASA astronaut Sandra Magnus joins Future of Space: Humankind's Leap Forward to discuss.
Clearing the COVID-19 Confusion
The CDC warns that COVID-19 is rapidly spreading with Omicron variant cases doubling every two days in the United States. How do current vaccines hold up against the new strain, and what does it mean for your upcoming holiday travel? Cheddar News breaks things down with infectious diseases specialist Dr. William Schaffner of Vanderbilt University School of Medicine.
U.S. Omicron Cases Surge as People Gear Up for Holiday Travel
President Joe Biden is expected to meet with his COVID-19 response team as the omicron variant continues to surge across the country. Experts say Delta is driving this surge but Dr. Anthony Fauci says Omicron will take over. Emergency physician Dr. Daniel Fagbuyi joins Cheddar News to discuss.
Covid Cases Surge As Omicron On Course To Become Dominant Strain
Omicron is on course to become the dominant COVID strain in the U.S., even as Delta is causing another spike in cases. According to Johns Hopkins University data, cases across the country are up 40% from last month, with New York City as a major hotspot. Outbreaks are now causing Broadway performances to be canceled, colleges and universities to shift to online classes, sports leagues to postpone games, and more. Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to discuss the surge in cases and how we can best protect ourselves against the new variant.
Load More